|
KMID : 0383820090660060444
|
|
Tuberculosis and Respiratory Diseases
2009 Volume.66 No. 6 p.444 ~ p.450
|
|
|
The Role and Significance of Biomarker for Plasma G-CSF in Patients with Primary Lung Cancer
|
|
Song Jung-Sub
Park Seong-Hoon
Yang Sei-Hoon
Kim Hak-Ryul
Jeong Eun-Taik
Kim So-Young
Park Jung-Hyun
Kim Hui-Jung
Lee Mi-Kyung
Shin Jeong-Hyun
Shin Seong-Nam
Jeong Jong-Hoon
Jo Hyang-Jeong
Lee Kang Kyu
Kim Dong
|
|
|
Abstract
|
|
|
Background: Biomarkers for cancer have several potential clinical uses, including the following: early cancer detection, monitoring for recurrence prognostication, and risk stratification. However, no biomarker has been shown to have adequate sensitivity and specificity. Many investigators have tried to validate biomarkers for the early detection and recurrence of lung cancer. To evaluate plasma G-CSF as such a biomarker, protein levels were measured and were found to correlate with the clinicopathological features of primary lung tumors.
Methods: Between December 2006 and May 2008, 100 patients with histologically-validated primary lung cancer were enrolled into this study. To serve as controls, 127 healthy volunteers were enrolled into this study. Plasma G-CSF levels were measured in lung cancer patients using the sandwich ELISA system (R & D inc.) prior to treatment.
Results: The mean plasma G-CSF levels were 12.2±0.3 pg/mL and 46.0±3.8 pg/mL (mean±SE) in the normal and in the cancer groups, respectively. In addition, plasma G-CSF levels were higher in patients with early lung cancer than in healthy volunteers (p<.001). Plasma G-CSF levels were higher in patients who were under 65 years old or smokers. Within the cancer group, plasma G-CSF levels were higher in patients with non small cell lung cancer than in patients with small cell lung cancer (p<.05). Overall, plasma G-CSF levels were shown to increase dependent upon the type of lung cancer diagnsosed. In the order from highest to lowest, the levels of plasma G-CSF tended to decrease in the following order: large cell carcinoma, squamous cell carcinoma, adenocarcinoma, and bronchioloalveolar carcinoma. Plasma G-CSF levels tended to be higher in patients with advanced TNM stage than in localized TNM stage (I, II
Conclusion: Plasma G-CSF level were significantly increased in patients with lung cancer, and in especially advanced TNM stage. These results suggest that plasma G-CSF can be used to support the diagnostic process of lung cancer staging and as an indicator of metastasis.
|
|
|
KEYWORD
|
|
|
Biological markers, Lung neoplasms, Granulocyte colony-stimulating factor, Metastasis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|